EP0446230A1 - Traitement de la myelosuppression associee a l'immunodeficience acquise - Google Patents

Traitement de la myelosuppression associee a l'immunodeficience acquise

Info

Publication number
EP0446230A1
EP0446230A1 EP89912836A EP89912836A EP0446230A1 EP 0446230 A1 EP0446230 A1 EP 0446230A1 EP 89912836 A EP89912836 A EP 89912836A EP 89912836 A EP89912836 A EP 89912836A EP 0446230 A1 EP0446230 A1 EP 0446230A1
Authority
EP
European Patent Office
Prior art keywords
csf
dhpg
pharmaceutical composition
effective amount
myelosuppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89912836A
Other languages
German (de)
English (en)
Inventor
Eric M. Bonnem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0446230A1 publication Critical patent/EP0446230A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • This invention relates to pharmaceutical compositions comprising an antiviral effective amount of DHPG, i.e. 9-(l,3-dihydroxy-2-propoxymethyl) guanine, in combination with an anti-myelosuppressive effective amount of GM-CSF, i.e. granulocyte macrophage colony stimulating factor, for use in treating patients suffering from myelosuppression and a viral infection associated with AIDS, i.e. Acquired Immune Deficiency Syndrome.
  • DHPG i.e. 9-(l,3-dihydroxy-2-propoxymethyl) guanine
  • GM-CSF i.e. granulocyte macrophage colony stimulating factor
  • AIDS Acquired Immune Deficiency Syndrome
  • HIV human immunodeficiency virus
  • the major effect of the AIDS virus is the incapacitation of the immune system, particularly T4 helper cells, which is the very system designed to fight against such invaders.
  • the fatal result of AIDS infection is the host defense defect that renders the body highly susceptible to opportunistic infections and neoplasms. Besides halting the AIDS virus itself. methods of treatment can be directed to lessening the effect of such opportunistic infections and neoplasms.
  • Cytomegalovirus (CMV) infection eventually develops in many patients having severe HIV disease as described in Quinnan et al., JAMA 1984, 252; 72-7; and Macher et al., N. Engl. J. Med. 1983, 309: 1454.
  • CMV is the most frequent cause of HIV-associated retinitis. See Glatt et al., N. Engl. J. Med. 1988, 318: 1439-48; and Georgia et al., Opthalmology 1984, 91: 1092-9.
  • Granulocyte macrophage colony stimulating factor is a lymphokine that exhibits a broad spectrum of immune cell stimulation as described in Burgess and Metcalf, Blood 1980, 56 947-58.
  • GM-CSF has been shown to increase .the leukocyte count in patients with the acquired immunodeficiency syndrome (Brandt e t al. , N. Engl. J. Med. 1988, 318: 869-76) and people suffering from chemotherapy-induced myelosuppression (Antman et al.. New Eng. J. Med.
  • colony stimulating factors alone may be a useful treatment of patients suffering from AIDS-type disease or together with erythropoietin and/or an antiviral agent and/or interleukin-2(IL-2) (PCT Application No. 87/03204).
  • one aspect of the present invention is a pharmaceutical composition comprising an antiviral effective amount of DHPG in combination with a anti-myelosuppressive effective amount of GM-CSF.
  • Another aspect involves administering to a patient suffering from cytomegalovirus retinitis an antiviral effective amount of DHPG in combination with an anti- myelosuppressive effective amount of GM-CSF.
  • the present invention also contemplates the use of DHPG for the preparation of a pharmaceutical composition for use in a combined therapy for treating a patient suffering from myelosuppression and a viral infection by administering DHPG in association with GM- CSF.
  • the present invention further contemplates the use of GM-CSF for the preparation of a pharmaceutical composition for use in a combined therapy for treating a patient suffering from myelosuppression and a viral infection by administering GM-CSF in association with DHPG.
  • the present invention still further contemplates the use of DHPG in association with GM-CSF -for the preparation of a pharmaceutical composition for treating a patient suffering from myelosuppression in association with a viral infection, said pharmaceutical composition comprising DHPG and GM-CSF together with pharmaceutical carriers therefor.
  • the present invention also provides the use of DHPG in combination with GM-CSF for treating a patient suffering fro myelosuppression and a viral infection.
  • the.present invention provides a process for the preparation of a pharmaceutical composition which comprises admixing DHPG and GM-CSF with pharmaceutically acceptable carriers therefor.
  • kits for use in treating patients suffering from myelosuppression and a viral infection comprising a pharmaceutical package having a first container and a second container, wherein the first container comprises an antiviral effective amount of a pharmaceutical composition containing DHPG and the second container comprises an anti-myelosuppressive amount of GM-CSF pharmaceutical composition.
  • DHPG [9-(l,3-Dihydroxy-2- propoxymethyl)guanine] , which is produced by Syntex Corporation, Palo Alto, California, and which may be obtained as described in U.S. Patent 4,355,032, can be administered in an amount so as to lessen the symptoms associated with cytomegalovirus retinitis. Such symptoms include production of a characteristic retinal lesion consisting of hemorrhagic exudates in a vascular pattern of distribution manifested clinically by decreased vision and/or blindness.
  • DHPG is administered in an amount of from about 5.0 to about 20 mg per kilogram per day.
  • the preferred administration regime is twice daily by intravenous infusion.
  • the DHPG is administered in an amount of from about 7.5 to about 15 mg per kilograms per day. The amount is adjusted based upon patient tolerance manifested by decreased white blood cell count.
  • GM-CSF Complementary DNAs
  • cDNAs Complementary DNAs
  • GM-CSF Complementary DNAs
  • non-recombinant GM-CSF has been purified from various culture supernatants, e.g. U.S. Patent 4,438,032 (Mo cell line); Burgers et al., Exp. Hematol. j ⁇ :893 (1981) (mouse); Sparrow et al., Proc. Natl. Acad. Sci., "82:292 (1985) (purification and partial amino acid sequence for mouse) ; Wu et al., Exp.
  • GM-CSF GM-CSF
  • the GM-CSF used in the present invention will be a human GM-CSF, most preferably the GM-CSF described in Proc. Natl. Acad. Sci. USA 82:4360 (1985) , which is hereby incorporated by reference.
  • GM-CSF is administered to a patient showing symptoms of CMV retinitis and who is being treated with DHPG as described above and who is experiencing a myelosuppression.
  • Myleosuppression for purposes of this invention is meant to include a reduction in the white blood cell count below about 2000 per cm 3 or a granulocyte count less than about 1000 per cm 3 .
  • the dosage for GM-CSF will vary according to the response observed. Generally, it is desirable to administer GM-CSF in a sufficient amount to maintain white blood cell counts from about 2000 to about 10,000 per cm 3 , preferably from "about 2000 to about 5,000 per cm 3 . A typical dosage of GM-CSF is about 3 to about 15 ⁇ g per kilogram per day intravenously or subcutaneously. Such white blood cell.levels will permit the full administration of DHPG and the prevention of further visual deterioration.
  • the usual time to efficacious rises in white blood cell count is 5 to 10 days after initiation of GM- CSF therapy. If no rise in white blood cell count has occurred, dosage may be adjusted by increasing increments of 25% every four days after day 10. If white blood cell count is greater than about 20,000 per cm 3 , dosage should be decreased by 25%. Dosage should be adjusted so that white blood cell count does not exceed about 20,000 per cm 3 .
  • the administration of the pharmaceutical compositions of this invention is via the subcutaneous or intravenous route.
  • DHPG and GM-CSF may be given together or sequentially, whichever is deemed more appropriate by the attending clinician.
  • the solutions to be administered may be reconstituted lypholized powders, particularly for GM-CSF and they may additionally contain preservatives, buffers, dispersahts etc.
  • GM- CSF is reconstituted with preservative-free sterile water with the maximum concentration not to exceed 1500 micrograms per ml. and administered subcutaneously or as a continuous infusion, depending on the urgency of the situation.
  • the daily dose is to be added to 50 ml of normal saline and the solution infused by mechanical pump.
  • kits for use in treating patients suffering from myelosuppression and a viral infection as discussed above.
  • the kits comprise a pharmaceutical package having a first container comprising a pharmaceutical composition containing an antiviral effective amount of DHPG and a second container comprising a pharmaceutical composition containing an anti-myelosuppressive amount of GM-CSF.
  • the kits or packages may also contain instructions for use of the pharmaceutical composition of DHPG and of GM- CSF in accordance with the present invention.
  • a 30 year old male was diagnosed as having AIDS and CMV retinitis.
  • treatment with DHPG was commenced and life threatening myelosuppression was the result.
  • a 100% dose of DHPG refers to a full protective dose or the recommended dose of DHPG of 15 mg per kilogram per day.
  • the dosage of DHPG was maintained until changed as indicated in Table 1 below.
  • Table 1 illustrates, administration of 10 mg of purified recombinant GM-CSF as described in Proc. Natl. Acad. Sci USA 82:4360 (1985) per kg by intravenous infusion drastically improved the white blood cell (WBC) count and permitted a return to a full protective dose of DHPG.
  • WBC white blood cell
  • Example 1 A 30 year old male was diagnosed as having AIDS and CMV retinitis. At Day 0, treatment with DHPG was commenced and a myelosuppression was the result. As the accompanying table illustrates, administration of GM-CSF, as described in Example 1, improved the white blood cell - (WBC) count and permitted a return to a full protective dose of DHPG as described in Example 1.
  • WBC white blood cell -
  • EXAMPLE 3 A 56 year old male was diagnosed as having AIDS and CMV retinitis. At Day 0, treatment with DHPG was commenced and a myelosuppression was the result. As the accompanying table illustrates, administration of GM-CSF, as described in Example 1, improved the white blood cell (WBC) count and permitted a return to a full protective dose of DHPG as described in Example l. Unfortunately, the patient developed thrombocytopenia during GM-CSF treatment and expired.
  • WBC white blood cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des compositions pharmaceutiques et des méthodes de traitement sont utiles pour le traitement de la myélosuppression et d'infections virales associées au SIDA, en particulier la rétinite du cytomégalovirus. De telles compositions et traitements utilisent une quantité antivirale efficace de 9-(1,3-dihydroxy-2-propoxyméthyle) guanine (DHPG) combinée à une quantité anti-myélosuppressive efficace du facteur de stimulation de colonies de granulocytes macrophages (GM-CSF). L'utilisation de DHPG et de GM-CSF pour la préparation d'une composition pharmaceutique utilisée dans ce traitement ainsi que des kits contenant des compositions pharmaceutiques comprenant DHPG et GM-CSF sont également décrits.
EP89912836A 1988-11-09 1989-11-07 Traitement de la myelosuppression associee a l'immunodeficience acquise Pending EP0446230A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26927688A 1988-11-09 1988-11-09
US269276 1988-11-09

Publications (1)

Publication Number Publication Date
EP0446230A1 true EP0446230A1 (fr) 1991-09-18

Family

ID=23026570

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89912836A Pending EP0446230A1 (fr) 1988-11-09 1989-11-07 Traitement de la myelosuppression associee a l'immunodeficience acquise
EP89311507A Ceased EP0370656A1 (fr) 1988-11-09 1989-11-07 Traitement de la suppression médullaire associée avec le SIDA

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP89311507A Ceased EP0370656A1 (fr) 1988-11-09 1989-11-07 Traitement de la suppression médullaire associée avec le SIDA

Country Status (11)

Country Link
EP (2) EP0446230A1 (fr)
JP (1) JPH0651639B2 (fr)
KR (1) KR960014097B1 (fr)
AU (1) AU630637B2 (fr)
CA (1) CA2002413A1 (fr)
DK (1) DK82191A (fr)
IL (1) IL92234A (fr)
MY (1) MY105868A (fr)
NZ (1) NZ231304A (fr)
WO (1) WO1990004973A1 (fr)
ZA (1) ZA898478B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3945393A (en) * 1992-04-14 1993-11-18 Schering Corporation Treatment of hepatitis with GM-CSF
EP0791061A4 (fr) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Animaux a rupture genique ciblee
US5585355A (en) * 1994-04-22 1996-12-17 Alkermes, Inc. Method for increasing blood-ocular barrier permeability with permeabilizer peptides
DE19802375A1 (de) * 1998-01-22 1999-07-29 Schenk Filterbau Gmbh Verfahren zur Entfernung und/oder Inaktivierung von Viren
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764742B2 (ja) * 1985-11-27 1995-07-12 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド Ａｉｄｓ型疾患治療用組成物
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9004973A1 *

Also Published As

Publication number Publication date
DK82191D0 (da) 1991-05-03
JPH0651639B2 (ja) 1994-07-06
MY105868A (en) 1995-02-28
DK82191A (da) 1991-05-03
CA2002413A1 (fr) 1990-05-09
IL92234A (en) 1993-06-10
AU4526889A (en) 1990-05-28
EP0370656A1 (fr) 1990-05-30
JPH04500210A (ja) 1992-01-16
AU630637B2 (en) 1992-11-05
KR960014097B1 (ko) 1996-10-14
ZA898478B (en) 1990-07-25
WO1990004973A1 (fr) 1990-05-17
IL92234A0 (en) 1990-07-26
KR900701301A (ko) 1990-12-01
NZ231304A (en) 1997-05-26

Similar Documents

Publication Publication Date Title
RU2128056C1 (ru) Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами
EP0246322B1 (fr) Traitement de maladies du type du sida
Walsh et al. A trial of recombinant human interleukin‐1 in patients with severe refractory aplastic anaemia
US5178855A (en) Treatment of luekocyte dysfunction with GM-CSF
EP0446230A1 (fr) Traitement de la myelosuppression associee a l'immunodeficience acquise
US5198417A (en) Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
JPH04360840A (ja) 血小板減少症治療剤
HU204711B (en) Process for producing pharmaceutical compositions comprising gamma-interferon and suitable for treating cancer of ovary
JPH0618783B2 (ja) 血小板血症治療用のヒトインタ−フエロンまたはそのハイブリツド含有医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19910420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89311507.1/0370656 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 10.12.91.